Alexander Kohlmann

TL;DR: In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalUTamide or monotherapy.

TL;DR: There are no specifically approved targeted therapies for the most common genomically defined subset of non–small cell lung cancer (NSCLC), KRAS-mutant lung cancer, and selumetinib to docetaxel alone as a second-line therapy did not improve progression-free survival.

TL;DR: A specific role for ZRSR2 in RNA splicing is identified and dysregulated splicing of U12-type introns is highlighted as a characteristic feature of Z RSR2 mutations in MDS.

TL;DR: It is demonstrated that successful ctDNA recovery for mutation detection in NSCLC is dependent on pre- Analytical steps and development of standardised methods for the detection of KRAS mutations from ct DNA specimens is recommended to minimise the impact of pre-analytical steps on mutation detection rates.